Detailed Scientific Programme

MONDAY 3RD OCTOBER 2022

TIME	SESSION NAME	ROOM
09:00-17:30	**Registration Open**	
12:00-17:00	**Exhibition and Poster Set Up**	
10:00-13:00	**Pre-Conference Workshop 1.1** Finding, critically appraising, and using a core outcome set (COS) for your trial *Paula Williamson, University of Liverpool* *Declan Devane, University of Galway* *Karen Matvienko-Sikar, University College Cork* *Sarah Gorst and Nicola Harman, University of Liverpool*	Queens Suite 1
	Pre-Conference Workshop 1.2 Introduction to optimisation experiments for complex interventions within the Multiphase Optimisation Strategy (MOST) framework *Samuel Smith, University of Leeds* *Michelle Collinson, University of Leeds* *Rebecca Walwyn, University of Leeds*	Queens Suite 2
	Pre-Conference Workshop 1.3 Using the PeRSEVERE guiding principles to prepare for and manage participation changes in clinical trials *William Cragg, University of Leeds* *Katie Gillies, University of Aberdeen* *Lauren Moreau, University of Leeds* *Puvan Tharmanathan, University of York*	Queens Suite 3
	Pre-Conference Workshop 1.4 Implementing CDISC's SDTM retrospectively for data sharing *Sharon Kean, University of Liverpool* *Jonathan Gibb, University of Liverpool* *Vicky Watson, University of Liverpool* *Carrol Gamble, University of Liverpool*	Queens Suite 4
	Pre-Conference Workshop 1.5 Estimands in randomised trials: practical guidance to help get the right answer to the right question *Brennan Kahan, University College London* *Suzie Cro, Imperial College London* *James Carpenter, University College London*	Queens Suite 5

TIME	SESSION NAME	ROOM
13:00-14:00	**Lunch Break (lunch not provided)**	
14:00-17:00	**Pre-Conference Workshop 2.1** How Routine Healthcare Data can enhance data-enabled clinical trials – what is available and what to consider before you apply *Macey Murray, University College London* *Suzanne Hartley, NHS Digital* *Matt Sydes, University College London* *Andy Rees, NHS Digital* *Louise Dunn, NHS Digital*	Queens Suite 1
	Pre-Conference Workshop 2.2 Clinical Trial Monitoring *Sharon Love, University College London* *Victoria Yorke-Edwards, University College London* *Lisa Fox, ICR-CTSU*	Queens Suite 2
	Pre-Conference Workshop 2.3 Planning & Delivering Effective and Engaging Training to Clinical Trial Staff *Sara T Brookes, University of Birmingham* *Razia Meer-Baloch, University of Birmingham*	Queens Suite 3
	Pre-Conference Workshop 2.4 Good practice in planning, conducting and reporting pilot trials *Sandra Eldridge, Queen Mary University of London* *Christine Bond, University of Aberdeen* *Mike Campbell, University of Sheffield* *Sally Hopewell, University of Oxford* *Gill Lancaster, Keele University* *Lehana Thabane, McMaster University* *Saskia Eddy, Queen Mary University of London* *Katie Mellor, University of Oxford*	Queens Suite 4

TUESDAY 4TH OCTOBER 2022

TIME	SESSION NAME	ROOM
08:00	**Registration and Speaker Preview Opens**	
08:45-09:00	**Welcome and Opening** *Matt Sydes, UCL* *Katie Gillies, University of Aberdeen* *Eleanor Mitchell, University of Nottingham* *Paula Williamson, University of Liverpool*	Auditorium
09:00-10:20	**Parallel Session 1A – Bayesian Approaches for Trials** *Chair: Deborah Stocken, University of Leeds*	Auditorium
	PS1A-01 A Bayesian Power Prior Approach for Incorporating Pilot Data into Cluster Randomised Controlled Trial Design: A hypothetical redesign and simulation study *Benjamin Gary Jones, University of Exeter*	
	PS1A-02 Sample size determination in basket trials: a Bayesian approach for borrowing of information *Haiyan Zheng, University of Cambridge*	
	PS1A-03 Bayesian Adaptive Clinical Trial Design using Integrated Nested Laplace Approximations *Anna Heath, The Hospital for Sick Children*	
	PS1A-04 A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials *Kristian Brock, UCB*	
	PS1A-05 Bayesian modelling strategies for borrowing of information in randomised basket trials *Luke Ouma, Newcastle University*	
	Parallel Session 1B – Trial Conduct Lessons *Chair: Suzanne Hartley, NHS Digital*	Queens Suite 1
	PS1B-01 Use of SWAT methodology to investigate intervention implementation processes – Case studies of two trials *Sadia Ahmed, Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds*	

TIME	SESSION NAME	ROOM
	PS1B-02 Using a simultaneous SWAT design to increase the recruitment and retention evidence base: two case studies *Elizabeth Coleman, York Trials Unit - University of York*	
	PS1B-03 Improving follow-up and retention to paediatric randomized controlled trials: a qualitative study *Daisy Mary Gaunt, Population Health Sciences, Bristol Medical School, University of Bristol*	
	PS1B-04 Effects on retention of different weight assessment approaches during trials of Behavioural Weight Management Interventions (BWMI). Nested Study within a Trial (SWAT) *Claire E Torrens, University of Stirling*	
	PS1B-05 Optimising the Notification Policy to Improve Engagement with an Alcohol Reduction App: Results from a Micro-Randomised Trial *Lauren Bell, London School of Hygiene & Tropical Medicine*	
	Parallel Session 1C – Challenges to Improving Accrual *Chair: Angela Meade, University College London*	Queens Suite 2
	PS1C-01 Behavioural Optimisation & Operational Strategies for Trials: The BOOST Approach *Katie Gillies, University of Aberdeen*	
	PS1C-02 Screening Log Guidelines (SLoG): A standardised model for screening data: who should be included and which data should be collected? *Susan Stirling, Juliet High, Norwich Clinical Trials Unit, University of East Anglia*	
	PS1C-03 The development of guidance for the use of eConsent by UKCRC Registered Clinical Trials Units *Duncan Appelbe, The University of Oxford*	
	PS1C-04 Inviting people to a clinical trial - how do we challenge the default decline response? *Shyma Jundi, NHS Digital*	
	PS1C-05 Optimization of the run-in stage in randomized clinical trials: an ensemble machine learning approach *Giulia Lorenzoni, University of Padova*	

TUESDAY 4TH OCTOBER 2022

TIME	SESSION NAME	ROOM
	Parallel Session 1D – Lightning Talk Session *Chair: Matt Sydes, UCL*	Kings Suite
	PS1D-LT03 Handling delayed toxicities in real-world oncology dose-finding trials: comparison of Continual Reassessment Method (CRM) and time-to-event CRM (TITE-CRM) *Zhulin Yin, Institute of Cancer Research*	
	PS1D-LT04 Updating existing core outcome sets to include LMiC participants: a meta core outcome set for stillbirth *Jamie Kirkham, The University of Manchester*	
	PS1D-LT05 The key elements of the core outcome set (COS) and the application of master protocol in the development of COS *Ruijin Qiu, Hongcai Shang, Dongzhimen Hospital, Beijing University of Chinese Medicine*	
	PS1D-LT07 Challenges of implementing and running a study within a trial (SWAT) across multiple host trials – the SPRUCE study *Morgaine Stiles, Institute of Cancer Research*	
	PS1D-LT08 A systematic review of the application of randomisation methodology in RCTs and association with study characteristics *Cydney Louise Bruce, University of Nottingham*	
	PS1D-LT10 RCT vs registry based observational studies in evaluating outcomes in spinal interventions *Lukas Staudt, University of Liverpool*	
	PS1D-LT11 The cost-effectiveness of improving patient recruitment in RCTs: a case-study of dexamethasone from the RECOVERY trial *Athanasios Gkekas, University of York*	
	PS1D-LT12 A comparison of methods for estimating dichotomous treatment effects: a simulation study *Jacqueline Thompson, University of Birmingham*	
	PS1D-LT13 Identification of causal mediation effects with non-adherence and missing data *Anca Maria Chis Ster, King's College London*	

TIME	SESSION NAME	ROOM
	PS1D-LT14 Ascertaining patient and clinician views on the severity of post-operative complications after cardiac surgery: design, conduct and analysis of a survey. *Rachel Maishman, University of Bristol*	
	PS1D-LT15 Enhancing the transparency and reporting of randomised trials: update of the SPIRIT 2013 and CONSORT 2010 Statements *Sally Hopewell, University of Oxford*	
	PS1D-LT16 Review of reporting of time to event analyses and the proportional hazards assumption in Randomised Controlled Trials *Ashma Krishan, University of Manchester*	
	PS1D-LT17 Public Perceptions of Clinical Research *Rachel Evans, NWORTH Clinical Trials Unit*	
	PS1D-LT18 Inclusion of stakeholders from low- and middle-income countries in core outcome set development and use *Jamlick Karumbi, University of Liverpool*	
	PS1D-LT19 Applying the Estimand Framework to the microbiological outcome *Mandy Lau, Cardiff University*	
	PS1D-LT20 Survey findings of the UK researchers about the challenges and barriers to blinding in complex intervention randomised controlled trials (RCTs) *Abdullah Yonis, University of Exeter*	
	PS1D-LT21 AlcoChange: Lessons for Stepped Wedge Trials after the Pandemic *Andrew Cook, University of Southampton*	
	PS1D-LT22 How COVID-19 policy changes during the Com-COV3 trial in adolescents impacted trial design and results *Melanie Greenland, University of Oxford*	
	PS1D-LT23 Conducting clinical trials during the COVID-19 pandemic: experiences from a dengue trial in Ho Chi Minh City, Vietnam *Nguyet Minh Nguyen, Oxford University Clinical Research Unit*	
	PS1D-LT24 Delivering COVID-19 Vaccine Trials at Speed: The ComFluCOV Experience *Sarah Baos, University of Bristol*	

TUESDAY 4TH OCTOBER 2022

TIME	SESSION NAME	ROOM
	PS1D-LT25 On registry-based randomized trials: Results and Lessons from the pan-Canadian AcT trial in acute ischemic stroke *Tolu Sajobi, University of Calgary*	
10:20-11:05	**Refreshment Break, Exhibition & Poster Viewing**	Studio One
11:05-12:25	**Parallel Session 2A – Healthcare Systems Data & Trials I** *Chair: Catrin Plumpton, Bangor University*	Auditorium
	PS2A-01 Priority setting the opportunities for routinely collected data and trials: COMORANT-UK *Michael Robling, Centre for Trials Research, Cardiff University*	
	PS2A-02 Demonstrating the data integrity of routinely collected healthcare systems data for clinical trials *Macey Murray, University College London*	
	PS2A-03 Big drug data for big drug trials – validation and data-driven implementation of routinely-collected, nationwide English prescribing and dispensing datasets in the RECOVERY trial *Guilherme Pessoa-Amorim, University of Oxford*	
	PS2A-04 Lack of standardised recording of inflammatory bowel disease outcomes in electronic health records in the UK: mind the data gap between clinical trials and practice *Violeta Razanskaite, University of Liverpool*	
	PS2A-05 A more efficient approach to randomised controlled trials in primary care using routinely collected practice-level data *Athene Lane, University of Bristol*	
	Parallel Session 2B – Improving Inclusivity *Chair: Andrew Cook, University of Southampton*	Queens Suite 1
	PS2B-01 Shining a light into the 'black box of horrendousness': a qualitative study exploring barriers and facilitators to conducting trials involving adults lacking capacity to consent *Victoria Shepherd, Cardiff University*	

TIME	SESSION NAME	ROOM
	PS2B-02 Beyond "must speak English": Systematic review of language-related eligibility criteria in patient recruitment to trials *Talia Isaacs, University College London*	
	PS2B-03 Increasing diversity and inclusion in clinical trials with underserved populations at risk for hepatitis C in Ho Chi Minh City, Viet Nam *Jennifer Ilo Van Nuil, Oxford University Clinical Research Unit*	
	PS2B-04 Comparing trial communication between patients from the most and least socio-economically disadvantaged backgrounds: qualitative findings from three studies embedded in cancer-related trials *Mariana Popa, University of Liverpool*	
	PS2B-05 How can we effectively engage diverse communities into clinical research? Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE and PANORAMIC Trials) *Mahendra G Patel, University of Oxford*	
	Parallel Session 2C – Improving Technology for Trials *Chair: Kerry Avery, University of Bristol*	Queens Suite 2
	PS2C-01 Designing devolved international databases in a UK-run international randomised trial platform in colorectal cancer (The FOxTROT Platform) *Geraldine Murden, University of Leeds*	
	PS2C-02 Evaluating the effect of regular symptom monitoring on trial outcomes: using electronic patient-reported outcome measures in an online eczema randomised controlled trial *Arabella Baker, University of Nottingham*	
	PS2C-03 Using two-way text messaging to collect daily pain outcome data in participants with Hidradenitis Suppurativa *Helen Stanton, Cardiff University*	
	PS2C-04 Development of a risk-based validation framework for central monitoring and statistical analysis scripts *Moniek Nelleke Bresser, Swiss Tropical and Public Health Institute*	
	PS2C-05 Textnums: A tool to streamline the use of analysis results in manuscripts *Rosanna Cretney, University of Oxford*	

TUESDAY 4TH OCTOBER 2022

TIME	SESSION NAME	ROOM
	Parallel Session 2D – Conduct & Analysis Lessons *Chair: Katie Gillies, University of Aberdeen*	Kings Suite
	PS2D-01 Investigating SMART analysis methods in late phase Myeloma trials: a simulation study *Jake Emmerson, University of Leeds*	
	PS2D-02 The UK Myeloma Research Alliance OPTIMUM trial: a synthetically-controlled phase II trial in a rare sub-population *Andrew Hall, Sarah Brown, University of Leeds*	
	PS2D-03 Overcoming the Challenges of Delivering a National Randomised Controlled Trial in Organ Donation *Amy Evans, NHSBT*	
	PS2D-04 Will (When to Induce Labour To Limit Risk in Pregnancy Hypertension) – A Multicentre Randomised Controlled Trial; Adaptations to Deliver a Trial During a Pandemic *Katie Kirkham, University of Birmingham*	
	PS2D-05 Integrating photovoice into a process evaluation: the case of the NightLife study *Victoria Cluley, University of Leicester*	
12:25-13:45	**Lunch Break, Exhibition & Poster Viewing**	Studio One
13:45-14:45	**Keynote Speaker – Clinical trials in pandemics: Challenges & Successes** *Professor Salim S. Abdool Karim, Centre for the Aids Programme of Research in South Africa (CAPRISA)*	Auditorium
14:45-15:15	**Refreshment Break, Exhibition & Poster Viewing**	Studio One
15:15-16:35	**Parallel Session 3A – Co-Producing Research I** *Chair: Frances Shiely, University College Cork* *Co-chair: Jim Elliott, Patient Partner, Pembrokeshire, UK*	Auditorium
	PS3A-01 Co-designing an adaptive clinical trials platform to slow the progression of multiple sclerosis *Jenny Robertson, Annee Amjad, University of Edinburgh*	
	PS3A-02 Co-producing an RCT with autistic adults: lessons on trial design and conduct for engaging perceived hard-to-reach populations *Alba Realpe, University of Bristol*	

TIME	SESSION NAME	ROOM
	PS3A-03 PPIE at the heart of the design of the NHS DigiTrials service *Susannah Strong, Heather Pinches, Leigh Mytton, NHS Digital*	
	PS3A-04 Moving from collaboration to co-production: exploring public and patient involvement in a methodology priority setting partnership *Nikita N Burke, Jim Elliot, Andrew Worrall, Evidence Synthesis Ireland*	
	PS3A-05 How to start a conversation with public partners about estimands: a practical tool *Suzie Cro, Imperial Clinical Trials Unit, Imperial College London*	
	Parallel Session 3B – Monitoring and Data Quality *Chair: Evelyne Kestelyn, Oxford University*	Queens Suite 1
	PS3B-01 What is the purpose of clinical trial monitoring? *Sharon Love, MRC Clinical Trials Unit at UCL*	
	PS3B-02 Artificial Intelligence in Trial Monitoring: Using Machine Learning to identify poor performance sites in clinical trials *Louise Coutts, Alan Turing Institute*	
	PS3B-03 THE COMPLIANCE PLOT: A novel bespoke approach to monitor and examine protocol-adherence in clinical trials *Hatem Wafa, King's College London*	
	PS3B-04 The power of visualising harm in randomised controlled trials *Victoria Cornelius, Imperial College London*	
	PS3B-05 Recommendations for visualising harms in randomised controlled trial publications: a consensus *Rachel Phillips, Queen Mary University London*	
	Parallel Session 3C – Adaptive Designs *Chair: Lehana Thabane, St Joseph's Healthcare*	Queens Suite 2
	PS3C-01 An enrichment trial design using joint modelling of longitudinal and time-to-event data *Abigail Burdon, University of Cambridge*	

TUESDAY 4TH OCTOBER 2022

TIME	SESSION NAME	ROOM
	PS3C-02 Combining factorial and MAMS platform designs to evaluate multiple interventions efficiently *Ian R White, UCL*	
	PS3C-03 Implementing the Bayesian Optimal Phase 2 design (BOP2) in a potentially practice-changing umbrella-basket platform trial for rare cancers: the DETERMINE trial *Lucinda Billingham, Cancer Research UK Clinical Trials Unit, University of Birmingham*	
	PS3C-04 An evaluation of the impact of outcome delay on multi stage trials *Aritra Mukherjee, James M. S. Wason, Michael Grayling, Newcastle University*	
	PS3C-05 A Practical Adaptive Designs Toolkit: Making adaptive designs more accessible *Munya Dimairo, University of Sheffield*	
	Parallel Session 3D – Spotlight Session **Update and Future Directions in Surgical Trials Methodology, Royal College of Surgeons of England Surgical Trials Centre (STC)** *Chair: Deborah Stocken, University of Leeds* *Peter Hutchinson, STC* *Jane Blazeby, STC Bristol* *David Beard, STC Oxford* *Marion Campbell, STC Aberdeen* *Joy Adamson, STC York*	Kings Suite

WEDNESDAY 5TH OCTOBER 2022

TIME	SESSION NAME	ROOM
08:00	**Registration and Speaker Preview Opens**	
08:30-09:50	**Parallel Session 4A – Improving Recruitment** *Chair: Kerry Avery, University of Bristol*	Auditorium
	PS4A-01 Using social media as recruitment tool in a dermatology clinical trial *Jaqueline Nuttall, University Of Southampton*	
	PS4A-02 Training trial Recruiters: An educational INtervention (TRAIN) for recruiters to neonatal trials *Valerie Smith, Trinity College Dublin*	
	PS4A-03 Effectiveness of a simple recruitment animation for increasing rates of recruitment and retention of ethnic minority participants in a large multicentre stroke trial: A SWAT *Nikola Sprigg, University of Nottingham*	
	PS4A-04 Questioning approaches to consent in time critical obstetric trials: insight from a mixed methods study within a trial *Kerry Woolfall, University of Liverpool*	
	PS4A-05 'A whole greater than the sum of its parts': synergies and outputs of a trials' conduct working group focused on Complex and Alternate Consent pathways. *Julia Wade, Amy M Russell, University of Bristol*	
	Parallel Session 4B – Collecting Evidence, Protecting Equipoise *Chair: Catrin Plumpton, Bangor University*	Queens Suite 1
	PS4B-01 A good use of time? Providing evidence for how effort is invested in primary and secondary outcome data collection in trials *Heidi Gardner, University of Aberdeen*	
	PS4B-02 Blinding Of Trial Statisticians: Developing guidance for a risk-proportionate approach to blinding statisticians within clinical trials *Christopher Partlett, University of Nottingham*	
	PS4B-03 Potential for bias due to unblinded outcome assessment in multi-arm multi-stage (MAMS) clinical trials *Jennifer Nicholas, London School of Hygiene & Tropical Medicine*	

TIME	SESSION NAME	ROOM
	PS4B-04 Total or Control Events: Choosing Approach for Timing of Trial Analyses *Babak Choodari-oskooei, UCL*	
	PS4B-05 Loss of equipoise: tackling the challenge in the Perfused Liver Utilisation Study *Helen Thomas, NHS Blood and Transplant CTU*	
	Parallel Session 4C – Issues in Outcome Measures *Chair: Evelyne Kestelyn, Oxford University*	Queens Suite 2
	PS4C-01 Trial designs with co-primary superiority and non-inferiority endpoints: methodological discussion points and practical guidance *Philip Pallmann, Cardiff University*	
	PS4C-02 Definitions, limitations, acceptability, guidance in use and reporting of surrogate endpoints in randomised controlled trials: A scoping review to support development of SPIRIT/CONSORT-SURROGATE *Anthony Muchai Manyara, University of Glasgow*	
	PS4C-03 Surrogate endpoints in regulatory use: how many are actually statistically valid? *Wang Pok Lo, Usher Institute, University of Edinburgh*	
	PS4C-04 The Win Ratio: A developing approach for analysing composite outcome measures in randomised controlled trials *Tim Clayton, London School of Hygiene & Tropical Medicine*	
	PS4C-05 Comparison of win ratio, win odds and win difference for dealing with composite outcomes *Duolao Wang, Gaohong Dong, Liverpool School of Tropical Medicine*	
	Parallel Session 4D – Complex Data Collection *Chair: Kirsteen Goodman, Glasgow Caledonian University*	Kings Suite
	PS4D-01 RACER-Knee and RACER-Hip: challenges of conducting randomised controlled trials of novel robotic interventions in the orthopaedic setting *James Griffin, University of Warwick*	
	PS4D-02 New frontiers in surgical site infection (SSI) assessment: developing reliable, valid and efficient electronic patient-reported methods for remote and blinded trial outcome assessment and follow-up *Rhiannon Macefield, University of Bristol*	

TIME	SESSION NAME	ROOM
	PS4D-04 Interpreting chaos: a priori account of expected variation in treatment compliance and fidelity *David Beard, University of Oxford*	
	PS4D-05 Measuring effectiveness in randomized controlled trials of complex interventions: examples from de-implementation research *Aleksi Raudasoja, Finnish Medical Society Duodecim*	
09:50-10:20	**Refreshment Break, Exhibition & Poster Viewing**	Studio One
10:20-11:40	**Parallel Session 5A – Communications I** *Chair: Frances Shiely, University College Cork* *Co-chair: Richard Stephens, Patient Partner*	Auditorium
	PS5A-01 What influences participant satisfaction with how trial results are shared with them? Patient and site staff views from the Show RESPECT study *Annabelle South, UCL*	
	PS5A-02 Integrated Participant Digital Storytelling (IPDS): an innovative method for disseminating complex participant stories *Clare Clement, University of Bristol*	
	PS5A-03 Use of the h-index and Scientific Quality Index to measure the quality of the output of health services researchers *Danielle Podmore, University of York*	
	PS5A-04 Reminding peer reviewers of the most important reporting guideline items to improve completeness in published articles: Primary results of two randomized controlled trials *Sally Hopewell, University of Oxford*	
	PS5A-05 Publication bias - a cross-sectional study of randomised trials in Sub-saharan Africa: ongoing challenges of research waste *Ameer Steven-jorg Hohlfeld, South African Medical Research Council*	
	Parallel Session 5B – Analysis I *Chair: Paula Williamson, University of Liverpool*	Queens Suite 1
	PS5B-01 Exploring Treatment Effect Heterogeneity and novel methods to obtain data driven subgroups: application to critical care randomised controlled trials *Eleanor Van Vogt, Imperial College London*	

TIME	SESSION NAME	ROOM
	PS5B-02 Estimating marginal treatment effects in multi-centre trials: design and analysis considerations. *Mollie Jessica Payne, King's College London*	
	PS5B-03 Subgroup analyses for continuous variables: A review of methods in randomised controlled trials *S. Faye Williamson, Newcastle University*	
	PS5B-04 Performance of interim analyses in a two-by-two factorial design with a time-to-event outcome: a simulation study of the VAPOR-C trial *Anurika Priyanjali De Silva, The University of Melbourne*	
	PS5B-05 Health economic analyses following an adaptive design: a simulation study in the group sequential design setting *Laura Flight, University of Sheffield*	
	Parallel Session 5C – Platform Protocol Lessons *Chair: Matt Sydes, UCL*	Queens Suite 2
	PS5C-01 Characteristics, progression, and output of randomized platform trials – a systematic survey *Alexandra Griessbach, University Hospital Basel*	
	PS5C-02 Deciding whether a multi-arm trial should adjust for multiple comparisons *Richard Parker, University of Edinburgh*	
	PS5C-03 Implementation of a novel dose allocation system for early phase platform trials with non-comparative arms *Alexandra Pitchford, Leeds Institute of Clinical Trials Research*	
	PS5C-04 Shifting the balance: optimising the design and delivery of trials with diverse comparisons *Loretta Davies, University of Oxford*	
	PS5C-05 Implementation of an Australian-wide master cancer protocol – an operational analysis of the Molecular Screening and Therapeutics program *Lucille Sebastian, University of Sydney*	
	Parallel Session 5D – Predicting Accrual *Chair: Kerry Woolfall, University of Liverpool*	Kings Suite
	PS5D-01 Back to the Future: using past recruitment data to predict future performance: retrospective analysis of a 10-year CTU portfolio *Eleanor J Mitchell, University of Nottingham*	

TIME	SESSION NAME	ROOM
	PS5D-02 Predicting participation in clinical trials to inform design choices *Nick Bansback, University of British Columbia*	
	PS5D-03 Recruitment patterns and prediction in randomized clinical trials – a meta-research study *Ala Taji Heravi, meta-research center*	
	PS5D-04 Predicting the impact of study design on participation rates: StudyGage – a simulation tool using patient choice data. *Kevin Marsh, Evidera*	
	PS5D-05 A practical approach to addressing barriers to trial participation for LGBTQIA+ people: progress of initiative by the NHMRC Clinical Trials Centre, The University of Sydney *Karen Bracken, NHMRC Clinical Trials Centre, The University of Sydney*	
11:40-11:50	**Room change**	
11:50-12:50	**Keynote Speaker: Doug Altman Memorial Lecture – Widening the impact of methodology research and good practice through guidelines** *Professor Isabelle Boutron, Université Paris Cité*	Auditorium
12:50-14:00	**Lunch Break, Exhibition & Poster Viewing**	Studio One
14:00-15:20	**Parallel Session 6A – Missing Data** *Chair: Michael Grayling, Newcastle University*	Auditorium
	PS6A-01 Sensitivity of results to missing data for clinical trials with discrete, longitudinal outcome measurements *Isabelle Smith, University of Leeds*	
	PS6A-02 Targeting the right population in trials with outcomes missing-at-random given covariates *Tim P. Morris, MRC Clinical Trials Unit at UCL*	
	PS6A-03 How much is that data in the window? A comparison of strategies for analysing data recorded outside pre-specified visit windows in randomised controlled trials *Nick Beckley-Hoelscher, King's College London*	
	PS6A-04 An extended 'tipping point' approach for missing data in binary outcomes when estimating relative risk in clinical trials *Catherine Moakes, University of Birmingham*	

TIME	SESSION NAME	ROOM
	PS6A-05 Treatment group outcome variance difference after dropout as an indicator of missing-not-at-random bias in randomized controlled trials *Audinga-Dea Hazewinkel, University of Bristol*	
	Parallel Session 6B – Reducing Trial Waste *Chair: Eleanor Mitchell, University of Nottingham*	Queens Suite 1
	PS6B-01 Quantifying the carbon footprint of current clinical trials: Development and prototype testing of a method to inform future lower carbon clinical trial design *Jessica Griffiths, Institute of Cancer Research*	
	PS6B-02 Moving towards sustainable clinical research *Sinead Holden, Maeve Kalusche, University College Dublin*	
	PS6B-03 Reducing the carbon footprint of the NightLife study *Niamh Quann, University of Leicester*	
	PS6B-04 Late-phase academic-led trials for potential regulatory use: Lessons and recommendations from one trials unit's experience *Victoria Yorke-Edwards, University College London*	
	PS6B-05 Tolerating bad trials: the continuing scandal *Shaun Treweek, University of Aberdeen*	
	Parallel Session 6C – Challenges in Improving Trials *Chair: Valerie Smith, Trinity College Dublin*	Queens Suite 2
	PS6C-01 How should I justify the sample size for my pilot trial? A methodological systematic review of sample size guidance for external randomised controlled pilot trials *Saskia Eddy, Queen Mary University of London*	
	PS6C-02 Recommendations for using progression criteria in external randomised pilot trials to determine feasibility *Katie Mellor, University of Oxford*	
	PS6C-03 Completion of PROMS – Electronic versus paper versus a Pandemic *Kirsteen Goodman, Glasgow Caledonian University*	
	PS6C-04 "Have you tried turning it off, and back on again?": Running trials involving digital home monitoring technologies – lessons from the I-TRAC feasibility Study *Carrie Stewart, University of Aberdeen*	

TIME	SESSION NAME	ROOM
	PS6C-05 A process evaluation and data triangulation of the Awareness and Beliefs About Cancer 3 trial *Yvonne Moriarty, Cardiff University*	
	Parallel Session 6D: Spotlight Session – Better Trials Together *Chair: Julia Brown, University of Leeds*	Kings Suite
	UKCRC CTU Network *Kerry Hood, Centre for Trials Research*	
15:20-15:50	**Refreshment Break, Exhibition & Poster Viewing**	Studio One
15:50-16:50	**Parallel Session 7A – Estimands** *Chair: Angela Meade, University College London*	Auditorium
	PS7A-01 Using estimands to inform trial choices: upending conventional wisdoms *Brennan Kahan, UCL*	
	PS7A-02 Accounting for use of rescue medication in mental health trials: application of the estimand framework for intercurrent events *Jennifer Hellier, Institute of Psychiatry, Psychology And Neuroscience, King's College London*	
	PS7A-03 Choosing estimands in hospice/palliative care clinical trials *Sabine Braat, University of Melbourne*	
	PS7A-04 Accounting for differential uptake of treatment-as-usual in open-label RCTs: a comparison of methods and illustration in mental health trials *Danielle Edwards, King's College London*	
	Parallel Session 7B – Core Outcome Set Methodology I *Chair: Katie Gillies, University of Aberdeen*	Queens Suite 1
	PS7B-01 A survey of knowledge, perceptions and use of core outcome sets among clinical trialists *Karen Matvienko-Sikar, University College Cork*	
	PS7B-02 Improving uptake of core outcome sets in clinical trials and systematic reviews *Paula Williamson, University of Liverpool*	
	PS7B-03 Multi-Round vs Real-Time Delphi for achieving consensus in core outcome set development: a randomised trial *Fiona Quirke, National University of Ireland, Galway*	

TIME	SESSION NAME	ROOM
	PS7B-04 Core outcome sets: Bridging the gap between research and routine care *Anna Kearney, University of Liverpool*	
	Parallel Session 7C – Statistical Issues *Chair: Munya Dimairo, University of Sheffield*	Queens Suite 2
	PS7C-01 Optimising First in Human trials via dynamic programming *Elizabeth Pitt, UCB*	
	PS7C-02 A road map for designing phase I clinical trials of radiotherapy-novel agent combinations *Sarah Brown, University of Leeds*	
	PS7C-03 Working under short timescales to deliver a national trial: a case study of the ComFluCOV trial from a statistician's perspective *Rosie A. Harris, Russell Thirard, Bristol Trials Centre, University of Bristol*	
	PS7C-04 Achieving consistency of results across statistical software packages for models with a random effect – why are our results not always replicable? *Jon Bishop, University of Birmingham*	
	Parallel Session 7D – Data & Participants *Chair: Kirsteen Goodman, Glasgow Caledonian University*	Queens Suite 3
	PS7D-01 How effective and acceptable is digital, multimedia information when recruiting children and young people to trials? *Peter Knapp, University of York*	
	PS7D-02 Randomised study within a trial (SWAT) of an enhanced patient information leaflet for recruitment of participants into a clinical trial of breast cancer treatment *Shabina Sadiq, University of Nottingham*	
	PS7D-03 A SWAT to determine the impact of data collection frequency on participant retention in a trial with decentralised follow up: The HEAL COVID Trial *Carrol Gamble, University of Liverpool*	
	PS7D-04 Developing principles for a more comprehensive, modernised approach to managing clinical trial participation changes through the UKCRC Registered CTU Network's PeRSEVERE project *William Cragg, Clinical Trials Research Unit*	
19:30-23:30	**Conference Dinner**	Royal Hall

THURSDAY 6TH OCTOBER 2022

TIME	SESSION NAME	ROOM
08:00	**Registration and Speaker Preview Opens**	
08:30-09:50	**Parallel Session 8A – Trial Data & Beyond** *Chair: Michael Grayling, Newcastle University*	Auditorium
	PS8A-01 What are the re-identification risk scores of publicly available anonymised clinical trial datasets? *Aryelly Rodriguez, The University of Edinburgh*	
	PS8A-02 Developing a prototype tool to aid mapping trial data to CDISC standards for Data Sharing *Jonathan Gibb, Liverpool Clinical Trials Centre, University of Liverpool*	
	PS8A-03 Generating High-Utility Synthetic Clinical Trial Data Using Non-Parametric Data-Augmented Multiple Imputation *Linke Li, University of Toronto*	
	PS8A-04 The End of Clinical Trials As We Know Them? The Role of In Silico Modelling in Surgical Trials *Deborah Stocken, University of Leeds*	
	PS8A-05 Developing and evaluating a tool for detecting problematic RCTs in health systematic reviews *Jack Wilkinson, University of Manchester*	
	Parallel Session 8B – Co-Producing Research II *Chair: Amanda Roberts, Patient Partner, Nottingham, UK* *Co-chair: Kirsteen Goodman, Glasgow Caledonian University*	Queens Suite 1
	PS8B-01 Perceptions of need and the decision to participate: a qualitative investigation of the experiences and perspectives of patients asked to take part in 3 RCTs *Nicola Farrar, University of Bristol*	
	PS8B-02 Co-produced resources to support patient and public involvement in developing core outcome sets – an e-toolkit and animation *Heather Barrington, University of Liverpool (COMET Initiative)*	
	PS8B-03 Patient and public involvement prior to trial initiation: lessons learnt for rapid partnership in the COVID-19 era *Zahra Jamal, London School of Hygiene & Tropical Medicine*	

TIME	SESSION NAME	ROOM
	PS8B-04 Patient and public involvement in numerical aspects of trials (PoINT): exploring patient and public partners' experiences and identifying stakeholder priorities *Beatriz Goulão, University of Aberdeen*	
	PS8B-05 Would you be happy to be contacted about research? *Sarah A Lawton, Keele University*	
	Parallel Session 8C - Healthcare Systems Data & Trials II *Chair: Andrew Cook, University of Southampton*	Queens Suite 2
	PS8C-01 Agreement and completeness of routine versus trial-specific patient outcome data : a systematic review *Saiam Ahmed, University College London*	
	PS8C-02 Leveraging Real-World Data for Time-to-Event Endpoints in Clinical Trials *Barbara Torlinska, University of Birmingham*	
	PS8C-03 Development of routine data based heart failure outcome ascertainment methods and application to the ASCEND trial *Michelle Abhayawardena Goonasekera, University of Oxford*	
	PS8C-04 Can we use routinely collected data for trial outcomes? Benefits, challenges and recommendations- a case study using the ISCOMAT cluster randomised trial among heart-failure patients *Ellen Mason, University of Leeds*	
	PS8C-05 Use of routine healthcare data in randomised implementation trials: a methodological systematic review *Charis Xuan Xie, Queen Mary University of London*	
	Parallel Session 8D: Spotlight Session *Chair: Tom Conway, NUI Galway*	Kings Suite
	HRB TMRN, Public communication about randomised trials *Sandra Galvin, HRB-TMRN Ireland* *Sinead Hynes, University of Galway* *Declan Devane, NUI Galway* *Simone Lepage, NUI Galway*	
09:50-09:55	**Room change**	
09:55-10:55	**Parallel Session 9A - Analysis II** *Chair: Munya Dimairo, University of Sheffield*	Auditorium
	PS9A-01 An innovative design tool for clinical trials with continuous monitoring of efficacy outcomes in rare diseases: efficacy transition pathways *Laura Kirton, University of Birmingham*	

TIME	SESSION NAME	ROOM
	PS9A-02 Visualising the impact of continuous covariates on time-to-event outcomes, an approach using weighted kernel estimators *Richard Jackson, University of Liverpool*	
	PS9A-03 Point estimation in exact two-stage group-sequential two-arm trial designs for binary outcome data *Michael Grayling, Janssen*	
	PS9A-04 Point estimation for adaptive trial designs: practical considerations and guidance *David Robertson, MRC Biostatistics Unit, University of Cambridge*	
	Parallel Session 9B - Core Outcome Set Methodology II *Chair: Valerie Smith, Trinity College Dublin*	Queens Suite 1
	PS9B-01 Developing a core outcome set for hand fractures and joint injuries in adults *Sandeep Rajiv Deshmukh, University of Nottingham*	
	PS9B-02 Development of a core outcome set with measurement instruments for research and clinical practice for Post COVID-19 condition (Long COVID) *Sarah Gorst, University of Liverpool*	
	PS9B-03 Ethical considerations for the inclusion of patient-reported outcomes in clinical research: The PRO ethics guidelines *Samantha Cruz Rivera, University of Birmingham*	
	PS9B-04 Development of core outcome sets for clinical trials of organisational and service level interventions: the RoboCOS study *Marion Campbell, University of Aberdeen*	
	Parallel Session 9C - Further Challenges *Chair: Kerry Woolfall, University of Liverpool*	Queens Suite 2
	PS9C-01 A hybrid approach to comparing parallel-group and stepped-wedge cluster randomized trials with a continuous primary outcome when there is uncertainty in the intra-cluster correlation. *Samuel Sarkodie, Newcastle University*	
	PS9C-02 The non-inferiority complex - a review and assessment of UK publicly funded non-inferiority trials *Nikki Totton, University of Sheffield*	
	PS9C-03 The Trials Communication Wheel: stakeholders to consider in the lifecycle of the trial *Frances Shiely, University College Cork*	

TIME	SESSION NAME	ROOM
	PS9C-04 Designs for parallel-group cluster-randomised trials, where the clusters are institutions: a classification system to aid identification, with six proposed sub-types *Laura E. Marsden, University of Leeds*	
	Parallel Session 9D – Lessons from the Pandemic *Chair: Matt Sydes, UCL*	Kings Suite
	PS9D-01 Learning from COVID-19 related trial adaptations to inform efficient trial design – a sequential mixed methods study *Robin Chatters, The University of Sheffield*	
	PS9D-02 Covid-19 experiences in Vietnam, Indonesia and Nepal translated into evidence based, consolidated learning in clinical research *Huong Thi Thanh Dau, Mutia Rahardjani, Samita Rijal, Oxford University Clinical Trial Unit, Ho Chi Minh City, Vietnam*	
	PS9D-03 Conducting UK clinical trials during and post the Covid-19 pandemic: impact, challenges and solutions *Ava Lorenc, University of Bristol*	
	PS9D-04 Hibernation or rapid set-up: lessons from three pandemic trials *Garry Meakin, Nottingham Clinical Trials Unit*	
10:55-11:20	**Refreshment Break, Exhibition & Poster Viewing**	Studio One
11:20-12:20	**Keynote Speaker: Designs for Randomised Phase III Clinical Trials How Have they Changed and How Might they Change? A Personal Perspective** *Professor Mahesh (Max) Parmar, UCL*	Auditorium
12:20-12:45	**Awards Ceremony & Conference Close** *Matt Sydes, UCL & Katie Gillies, University of Aberdeen*	Auditorium
13:00-16:00	**Post-Conference Workshop 3.1** Statistical and practical aspects of the design and analysis of Multi-Arm Multi-Stage (MAMS) Platform Trials *Babak Choodari-Oskooei, University College London* *Matt Sydes, University College London* *Max Parmar, University College London*	Queens Suite 1
	Post-Conference Workshop 3.2 eConsent in clinical trials *Members of the UKTMN, TMRP and UKCRC CTU eConsent collaborative group*	Queens Suite 2
	Post-Conference Workshop 3.3 Triangulating evidence from observational data and randomized controlled trials for precision medicine *Jack Bowden, University of Exeter* *Beverley Shields, University of Exeter*	Kings Suite

Educational Workshops are priced at £70 and places are still available. Visit the conference website ictmc.org/workshops to book now.